Scholarlink

<p>The overexpression of epidermal growth factor receptor (EGFR) in various cancer types makes it an attractive target for therapeutic intervention. In this study, we designed a novel peptibody, FcIgG-GE11-Melittin, by fusing Melittin, a cytotoxic peptide from bee venom, to an EGFR-targeting peptibody (FcIgG-GE11). The FcIgG-GE11 component ensures specific binding to EGFR-overexpressing cancer cells, while Melittin induces cell death through its lytic activity. We evaluated the efficacy of FcIgG-GE11-Melittin in vitro using EGFR-overexpressing cancer cell lines. Our results demonstrate that FcIgG-GE11-Melittin selectively targets and kills EGFR-positive cancer cells while sparing normal cells. These findings highlight the potential of FcIgG-GE11-Melittin as a targeted therapeutic agent for EGFR-overexpressing cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月3日

查看全文
  • Malihe Hallaji,
  • Shima Fayaz,
  • Mojgan Allahyari,
  • Majid Golkar,
  • Kamran Pooshang-Bagheri,
  • Pezhman Fard-Esfahani

摘要

The overexpression of epidermal growth factor receptor (EGFR) in various cancer types makes it an attractive target for therapeutic intervention. In this study, we designed a novel peptibody, FcIgG-GE11-Melittin, by fusing Melittin, a cytotoxic peptide from bee venom, to an EGFR-targeting peptibody (FcIgG-GE11). The FcIgG-GE11 component ensures specific binding to EGFR-overexpressing cancer cells, while Melittin induces cell death through its lytic activity. We evaluated the efficacy of FcIgG-GE11-Melittin in vitro using EGFR-overexpressing cancer cell lines. Our results demonstrate that FcIgG-GE11-Melittin selectively targets and kills EGFR-positive cancer cells while sparing normal cells. These findings highlight the potential of FcIgG-GE11-Melittin as a targeted therapeutic agent for EGFR-overexpressing cancers.